Work

Phase 1 Trial Of Bone Marrow Stromal Cells (Bone Marrow-derived MSCS) To Treat Tissue Damage In Allogeneic Stem Cell Transplant Recipients: Biological Markers Correlate With Clinical Responses and Survival

Year: 2013

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v122.21.3282.3282

Authors: Minoo Battiwalla, Fang Yin, Sawa Ito, Xingmin Feng, Fariba Chinian, J. Joseph Melenhorst, Eleftheria K Koklanaris, Marianna Sabatino, David Stroncek, Leigh Samsel, Jeffrey K. Klotz, Nancy F. Hensel, Pamela Robey, A. John Barrett

Institutions: National Institutes of Health, National Heart, Lung, and Blood Institute, Abramson Cancer Center, University of Pennsylvania, Madigan Army Medical Center, National Institute of Dental and Craniofacial Research

Language: English

Topic: Hematopoietic Stem Cell Transplantation

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2479856948

FWCI:

Cites:

Cited by:

Related to: 10